Tessera Therapeutics Attracts Over $230M in Series B Financing to Advance ‘Gene Writing’ – A New Category in Genetic Medicine SoftBank Vision Fund 2, Alaska Permanent Fund Corporation, Altitude Life Science Ventures, Qatar Investment Authority, and Other New Investors Provide Growth Capital to Fuel Pioneering Platform from Flagship Labs CAMBRIDGE, Mass., January 12, 2021-- Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised over $230M in Series B financing.